-
Readying for the Second Wave: What, When, and How Must Orphan Medicine Manufacturers Prepare for EU HTAR?
Sep 9, 2025, 16:22 PM -
Estimation of Utility Weights for Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent Bruton Kinase Inhibitor (cBTKi)
Sep 9, 2025, 16:22 PM -
Feasibility Assessment of Real-World Data for Trial Emulations: A Methodological Framework
Sep 9, 2025, 16:22 PM -
Impact of RSV Infection on Acute Otitis Media Burden in Young Children Beyond Their First Year of Life in Japan
Sep 9, 2025, 16:22 PM -
Caregiver QALYs Deserve Better: Why It's Time for a Methodological Rethink
Sep 9, 2025, 16:22 PM -
Early Impact of the Mazars Review on Reimbursement Timelines in Ireland
Sep 9, 2025, 16:22 PM -
Pharmacists’ Engagement With Pharmaceutical Care in Pakistan: Insights From a Cross-Sectional Survey on Knowledge, Attitudes, Practices, and Barriers
Sep 9, 2025, 16:22 PM -
Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme
Sep 9, 2025, 16:22 PM -
Paving the Path to Success for Joint Clinical Assessments: One Asset at a Time
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population
Sep 9, 2025, 16:22 PM -
An Interactive R-Shiny Application for Budget Impact Modeling of Cell and Gene Therapies With Multiple Innovative Payment Scenarios
Sep 9, 2025, 16:22 PM -
Current Treatment Pathway for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in England: Insights From a Qualitative Validation With Clinical Experts
Sep 9, 2025, 16:22 PM -
Solving the PICO Puzzle: Perspectives on Outcome Measures for Oncology Medicines in Assessments of the European Medicines Agency and Health Technology Assessment Organizations in Europe
Sep 9, 2025, 16:22 PM -
Barriers and Facilitators Influencing the Development of Complex Generics: An Exploratory Study
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review of the Mitigation Strategies to Overcome the Risk for Confounding of Overall Survival in Trials With Crossover/Treatment Switching Evaluated in Health Technology Assessments of Treatments for Select Tumors in Oncology
Sep 9, 2025, 16:22 PM -
Systems-Level Modeling Approaches for Complex Health Technologies: A Systematic Review
Sep 9, 2025, 16:22 PM -
Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide
Sep 9, 2025, 16:22 PM -
Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics
Sep 9, 2025, 16:22 PM -
Access to Decide on a Generalization: Results From the EVA-Corse Experiment: Efficiency and Clinical Non-Inferiority of a Hybrid Cardiac Rehabilitation Model in Corsica
Sep 9, 2025, 16:22 PM -
Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM
